<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299090</url>
  </required_header>
  <id_info>
    <org_study_id>PEL-09-02</org_study_id>
    <nct_id>NCT01299090</nct_id>
  </id_info>
  <brief_title>Prospective Pellevé™ Neck Wrinkle Study</brief_title>
  <official_title>Prospective Pellevé™ Neck Wrinkle Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ellman International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ellman International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of RF device to treat wrinkles of the neck
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study evaluating the safety and efficacy of two treatments, spaced at
      30 day intervals, using the Surgitron® Dual RF™ S5 with the Pellevé™ wrinkle treatment
      handpiece and Pellevé™ treatment gel for the treatment of neck wrinkles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Neck and Facial Wrinkles Using the Fitzpatrick Wrinkle Assessment</measure>
    <time_frame>90 days post treatment</time_frame>
    <description>Three independent investigators blinded to photography time points will perform retrospective evaluations of photography from all visits using the 9-point Fitzpatrick Wrinkle Assessment Scale for assessment of neck and facial wrinkles at the culmination of the study.
The measurement is for percentage of patients who showed improvement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>90 days post treatment</time_frame>
    <description>The rate of adverse events will be assessed throughout the duration of the study</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Facial and Neck Rhytides</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects enrolled were in the treatment group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator</intervention_name>
    <description>two treatments spaced 30 days apart</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  30-70 years of age

          -  Subjects with clinical evidence of neck wrinkles moderate to severe in severity as
             specified by a grade 4-9 on the Fitzpatrick Wrinkle Assessment Scale.

          -  Willingness and ability to comply with protocol requirements, including returning for
             follow-up visits and abstaining from exclusionary procedures for the duration of the
             study.

          -  Willingness and ability to provide written photo consent and adherence to photography
             procedures(i.e., removal of jewelry and makeup).

          -  Willingness and ability to provide written informed consent prior to performance of
             any study related procedure.

        Exclusion Criteria:

          -  Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a
             reliable form of birth control.

          -  Subjects who have had prior exposure to any hyaluronic acid, or any other filler,
             injection for any purpose in the 12 months preceding study enrollment through the
             duration of the study.

          -  Subjects who have had prior exposure to any botulinum toxin for rhytids in the
             treatment area in the 6 months preceding study enrollment through the duration of the
             study.

          -  Subjects who have had a prior cosmetic procedure to improve rhytids in the treatment
             area (i.e.,rhytidectomy, CO2/erbium laser resurfacing, Thermage/Thermacool
             radiofrequency treatment)within 12 months or who have visible scars that may affect
             evaluation of response and/or quality of photography.

          -  Microdermabrasion, or prescription level glycolic acid treatments within 3 months
             prior to study participation or during the study.

          -  Active cut, wound, or infection on the skin.

          -  Oral Isotretinon within the past 12 months.

          -  Active HSV-1.

          -  History of keloids or hypertrophic scarring.

          -  Existing or history of skin malignancy in the treatment area during the past 12
             months.

          -  Existing or history of skin disease in the treatment area during the past 12 months.

          -  History of collagen or vascular disease.

          -  Subjects who have implantable pacemaker, automatic implantable defibrillator/
             cadioversor (AICD), or any other implantable electric device.

          -  Subjects who have used, within 30 days, any medication that can cause dermal
             hypersensitivity or affect skin characteristics.

          -  History of autoimmune disease.

          -  History of any disease that inhibits pain sensation.

          -  History of Diabetes I or II.

          -  Concurrent therapy that, in the investigator's opinion, would interfere with the
             evaluation of the safety or efficacy of the study medication.

          -  Subjects who anticipate the need for surgery or overnight hospitalization during the
             study.

          -  Subjects who, in the Investigator's opinion, have a history of poor cooperation,
             noncompliance with medical treatment or unreliability.

          -  Enrollment in any active study involving the use of investigational devices or drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Chipps, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moy-Fincher-Chipps Facial Plastics/Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moy-Fincher-Chipps Facial Plastics/Dermatology</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <results_first_submitted>November 9, 2014</results_first_submitted>
  <results_first_submitted_qc>November 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2014</results_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wrinkles</keyword>
  <keyword>rhytides</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>All subjects enrolled were in the treatment group.
Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator: two treatments spaced 30 days apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>All subjects enrolled were in the treatment group.
Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator: two treatments spaced 30 days apart</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Neck and Facial Wrinkles Using the Fitzpatrick Wrinkle Assessment</title>
        <description>Three independent investigators blinded to photography time points will perform retrospective evaluations of photography from all visits using the 9-point Fitzpatrick Wrinkle Assessment Scale for assessment of neck and facial wrinkles at the culmination of the study.
The measurement is for percentage of patients who showed improvement</description>
        <time_frame>90 days post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>All subjects enrolled were in the treatment group.
Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator: two treatments spaced 30 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Neck and Facial Wrinkles Using the Fitzpatrick Wrinkle Assessment</title>
          <description>Three independent investigators blinded to photography time points will perform retrospective evaluations of photography from all visits using the 9-point Fitzpatrick Wrinkle Assessment Scale for assessment of neck and facial wrinkles at the culmination of the study.
The measurement is for percentage of patients who showed improvement</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>The rate of adverse events will be assessed throughout the duration of the study</description>
        <time_frame>90 days post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>All subjects enrolled were in the treatment group.
Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator: two treatments spaced 30 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>The rate of adverse events will be assessed throughout the duration of the study</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>All subjects enrolled were in the treatment group.
Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator: two treatments spaced 30 days apart</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Chipps, MD</name_or_title>
      <organization>Moy, Fincher, Chipps Medical Group</organization>
      <phone>(310) 274-5372</phone>
      <email>lchipps@ucla.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

